We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Unveils New Approach for Cost-Benefit Assessments
ICER Unveils New Approach for Cost-Benefit Assessments
The Institute for Clinical and Economic Review (ICER) has updated its drug value assessment process for 2020 to include more real-world evidence, a one-year reevaluation and other new elements.